OIPE JC180
MAR 0 9 2004
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	ATTY. DOCKET NO. PC25185A	SERIAL NO. 10/689,773
	APPLICANT COLON-CRUZ, ET AL.	
	FILING DATE OCTOBER 21, 2003	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EB		5 2 0 6 3 6 6	4/27/93	BOWLES	544	284	
EB		5 3 1 2 9 2 5	5/17/94	ALLEN, ET AL.	544	368	
EB		5 9 3 5 9 6 0	8/10/9	WALINSKY, ET AL.	514	253	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
EB		0 7 9 0 2 3 6	08/20/97	EPO	—	—		
EB		0 0 1 0 9 7 5	03/02/00	PCT	—	—		

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

1.	EB	Hans Bundgaard; Elsevier Science Publishers B.V.; Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities; (1985); p. 1-10.
2.	EB	Davis, et al.; CNS Drugs; Ziprazidone; (1997) vol. 8. No. 2; p. 153-159.
3.	EB	Caley, et al.; The Annals of Pharmacotherapy; Ziprasidone: The Fifth Atypical Antipsychotic; (2002) vol. 36, no. 5; p. 839-851.

EXAMINER E Bernhard DATE CONSIDERED 5/27/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.